Related Experiment Videos
[Cerebral infarct in systemic lupus erythematosus]
F M Sánchez-Caballero1, J L Marenco, J Sánchez-Bursón
1Sección de Neurología, Hospital Universitario de Valme, Sevilla, España. fsanchezc@meditex.es
Revista De Neurologia
|January 19, 2000
Summary
Cerebral infarcts are an uncommon complication of active systemic lupus erythematosus (SLE), often linked to antiphospholipid antibodies or cardiogenic issues. Early treatment with immunosuppressants and anticoagulants improves outcomes.
Area of Science:
- Rheumatology
- Neurology
- Immunology
Background:
- Systemic lupus erythematosus (SLE) is a complex autoimmune disease with diverse clinical manifestations.
- Stroke is a rare but serious complication of SLE, arising from various etiopathogenic mechanisms.
- Understanding the incidence and characteristics of stroke in SLE is crucial for patient management.
Observation:
- This study analyzed six patients with cerebral infarcts and SLE, revealing a 6% incidence in the SLE cohort.
- Cerebral infarcts occurred during active SLE phases, with antiphospholipid antibodies (33%) and cardiogenic embolism (33%) being significant contributing factors.
- Patients often required cyclophosphamide for severe SLE and anticoagulants for antiphospholipid syndrome or suspected thromboembolism.
Findings:
- The incidence of cerebral infarct in SLE is low, typically occurring in active, advanced stages of the disease.
- Multiple etiopathogenic mechanisms, including antiphospholipid antibodies and cardiogenic embolism, often coexist, complicating the identification of the primary cause.
- Early detection of antiphospholipid antibodies is essential for managing stroke risk in SLE patients.
Implications:
- Stroke in SLE necessitates a comprehensive approach, considering multiple potential causes.
- Prompt initiation of immunosuppressive and anticoagulant therapies is vital for favorable patient outcomes.
- Further research into the specific interplay of SLE-related factors and cerebrovascular events is warranted.